Clinical Trial Update: Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on developing FAPI PET imaging as a non-invasive biomarker for pulmonary fibrogenesis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis

Drugs mentioned

• FAPI-PET imaging tracer (Fibroblast Activation Protein Inhibitor (FAPI))

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Fibrosis Lung | Phase 2 | Status: RECRUITING